José Fernando Molina

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Bente Langdahl, Cesar Libanati, Daria B. Crittenden et al. · The Lancet · 2017 · 467 citations

Medicine, Endocrinology, Pharmacotherapy +14

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis

Sergio Gutiérrez‐Ureña, José Fernando Molina, M L Cuéllar et al. · Arthritis & Rheumatism · 1996 · 280 citations

Medicine, Pharmacology, Pharmacotherapy +11

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 169 citations

Pharmacy, Pharmacotherapy, Bone Metabolism +10

Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor α protective?

Diana Gómez, P Corréa, Luis Miguel Gómez et al. · Seminars in Arthritis and Rheumatism · 2004 · 161 citations

Life Sciences, Immunology, Autoimmunity +15

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)

Bernardo A. Pons‐Estel, Eloísa Bonfá, Enrique R. Soriano et al. · Annals of the Rheumatic Diseases · 2018 · 151 citations · Full text

Life Sciences, Immunology, Internal Medicine +10